Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
2
50%
Ph phase_2
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

completed125%
active_not_recruiting250%
recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_2

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

NCT06561074
active_not_recruitingphase_1

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

NCT05034627
active_not_recruitingphase_1

2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML

NCT04953780
completedphase_3

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034

Clinical Trials (4)

Showing 4 of 4 trials
NCT06561074Phase 2

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

Recruiting
NCT05034627Phase 1

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active Not Recruiting
NCT04953780Phase 1

2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML

Active Not Recruiting
NCT00671034Phase 3

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4